Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on December 6, 2013, reporting events occurring on December 4, 2013. The filing details the entry into a material definitive agreement for a private placement of common stock.
Key Financial Metrics
- Capital Raised: Gross proceeds of $2.2 million from the issuance of 550,000 shares of common stock at $4.00 per share.
- Transaction Costs: $154,000 paid in placement agent commissions to Dawson James Securities, Inc.
- Use of Proceeds: Net proceeds are designated for working capital and general corporate purposes.
- Warrant Issuance: A warrant was issued to the placement agent to purchase up to 16,500 shares at an exercise price of $5.00 per share, expiring May 3, 2016.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement on December 4, 2013, increasing the company's equity capital. The offering is expected to close on or about December 9, 2013, subject to customary closing conditions. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a current event report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
Management anticipates utilizing the net proceeds to support working capital needs. The filing includes standard forward-looking statements regarding future activities and expectations, noting that actual results may differ materially due to risks and uncertainties. The offering is contingent upon the satisfaction of customary closing conditions and is subject to state securities laws.
Investor Verification Checklist
- Verify the closing date of the offering (expected December 9, 2013) and confirmation of fund receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Confirm the impact of the 16,500 warrant shares on future dilution.
- Check subsequent filings for updates on the use of proceeds and any changes to the company's liquidity position.